Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kim G. Hilbish"'
Autor:
Matthew Schroeder, Kelly M. Credille, Darryl Ballard, Jeffrey C. Hanson, Kim G Hilbish, Gary A. Boorman, Armando R. Irizarry Rovira, Andrea Niedenthal
Publikováno v:
Toxicologic pathology. 49(5)
The tolerability of single daily gavage doses of 0.5% or 2.0% (wt/vol) sodium lauryl sulfate (SLS) in 11- to 12-week-old male CD-1 mice was evaluated in a study of 3 months in duration. Live-phase, gross necropsy, and histopathologic parameters were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575573062a61caf8c17530cb05b7fe46
https://pubmed.ncbi.nlm.nih.gov/33942680
https://pubmed.ncbi.nlm.nih.gov/33942680
Publikováno v:
Birth Defects Research. 109:513-527
Background The purpose of these studies was to evaluate the effects of evacetrapib on male and female fertility and on embryo-fetal development (EFD). Methods Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c209ecb115bb4528de36b8e82949f24d
https://doi.org/10.1002/bdr2.1022
https://doi.org/10.1002/bdr2.1022
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 107:174-184
A humanized monoclonal antibody targeting transforming growth factor β1 (TGF-β1 mab) has been used in development for the treatment of chronic kidney disease. Embryo-fetal development studies were conducted in rats and rabbits using 30 and 25 anima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52a7a49c12d45c72f2cc250aa9a26585
https://doi.org/10.1002/bdrb.21182
https://doi.org/10.1002/bdrb.21182
Publikováno v:
Reproductive Toxicology. 58:160-173
The reproductive and developmental toxicity of ixekizumab, a selective inhibitor of interleukin-17A (IL-17A), was assessed in the following studies in cynomolgus monkeys: fertility (3-month dosing), embryo-fetal development (EFD; dosing from gestatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afc862ddd53d6c2268ba1325b9e26fea
https://doi.org/10.1016/j.reprotox.2015.10.008
https://doi.org/10.1016/j.reprotox.2015.10.008
Publikováno v:
Birth defects research. 110(18)
BACKGROUND Olaratumab (Lartruvo™) is a recombinant human IgG1 monoclonal antibody that specifically binds PDGFRα. The maternal and in utero embryo-fetal toxicity and toxicokinetics of a human anti-mouse PDGFRα antibody (LSN3338786) were investiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71458a6ecbcaa2b1de6c49ad906fe660
https://pubmed.ncbi.nlm.nih.gov/30367709
https://pubmed.ncbi.nlm.nih.gov/30367709
Publikováno v:
Birth defects research. 109(7)
Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), was under development for the treatment of cardiovascular (CV) disease. The purpose of this pre-postnatal study in rabbits was to evaluate the effects of evac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b40b4be6c5cb2b52ad9ff0f9b11bfd68
https://pubmed.ncbi.nlm.nih.gov/28398632
https://pubmed.ncbi.nlm.nih.gov/28398632
Publikováno v:
Birth defects research. 109(7)
The purpose of these studies was to evaluate the effects of evacetrapib on male and female fertility and on embryo-fetal development (EFD).Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), was administered da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7cf9cdd0135332140f5ef94fbebe1f91
https://pubmed.ncbi.nlm.nih.gov/28398618
https://pubmed.ncbi.nlm.nih.gov/28398618
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 98:400-415
LY500307 is a selective estrogen receptor beta (ERβ) agonist that was developed for the treatment of benign prostatic hyperplasia. The in vitro functional selectivity of LY500307 for ERβ agonist activity is 32-fold above the activity at the alpha r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90e10c1524f3b88ad7f213ba810b8682
https://doi.org/10.1002/bdrb.21083
https://doi.org/10.1002/bdrb.21083
Publikováno v:
Birth defects research. Part B, Developmental and reproductive toxicology. 107(4-5)
A humanized monoclonal antibody targeting transforming growth factor β1 (TGF-β1 mab) has been used in development for the treatment of chronic kidney disease. Embryo-fetal development studies were conducted in rats and rabbits using 30 and 25 anima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9370f3faf035aac0f5f014294de2e3a
https://pubmed.ncbi.nlm.nih.gov/27519584
https://pubmed.ncbi.nlm.nih.gov/27519584
Autor:
William J, Breslin, Kim G, Hilbish, Jennifer A, Martin, Carolyn A, Halstead, Deanna L, Newcomb, Gary J, Chellman
Publikováno v:
Birth defects research. Part B, Developmental and reproductive toxicology. 104(3)
Tabalumab, a human IgG4 monoclonal antibody (mAb) with neutralizing activity against both soluble and membrane B-cell activating factor (BAFF), has been under development for the treatment of autoimmune diseases. The purpose of this study was to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2234542dc76b109c63ff7cf6f65667be
https://pubmed.ncbi.nlm.nih.gov/26195230
https://pubmed.ncbi.nlm.nih.gov/26195230